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Since its discovery, myostatin (MSTN) has been at the forefront of muscle therapy research because 
intrinsic mutations or inhibition of this protein, by either pharmacological or genetic means, result in 
muscle hypertrophy and hyperplasia. In addition to muscle growth, MSTN inhibition potentially disturbs 
connective tissue, leads to strength modulation, facilitates myoblast transplantation, promotes tissue 
regeneration, induces adipose tissue thermogenesis and increases muscle oxidative phenotype. It is also 
known that current advances in gene therapy have an impact on sports because of the illicit use of such 
methods. However, the adverse effects of these methods, their impact on athletic performance in humans 
and the means of detecting gene doping are as yet unknown. The aim of the present review is to discuss 
biosynthesis, genetic variants, pharmacological/genetic manipulation, doping and athletic performance 
in relation to the MSTN pathway. As will be concluded from the manuscript, MSTN emerges as a 
promising molecule for combating muscle wasting diseases and for triggering wide-ranging discussion 
in view of its possible use in gene doping.
Uniterms: Myostatin. Myostatin/genetic variants. Myostatin/pharmacological inhibitors. Gene doping. 
Gene therapy. Physical performance. Skeletal muscle.
Desde sua descoberta, a miostatina (MSTN) entrou na linha de frente em pesquisas relacionadas às terapias 
musculares porque mutações intrínsecas ou inibição desta proteína tanto por abordagens farmacológicas 
como genéticas resultam em hipertrofia muscular e hiperplasia. Além do aumento da massa muscular, 
a inibição de MSTN potencialmente prejudica o tecido conectivo, modula a força muscular, facilita o 
transplante de mioblastos, promove regeneração tecidual, induz termogênese no tecido adiposo e aumenta 
a oxidação na musculatura esquelética. É também sabido que os atuais avanços em terapia gênica têm 
uma relação com o esporte devido ao uso ilícito de tal método. Os efeitos adversos de tal abordagem, seus 
efeitos no desempenho de atletas e métodos para detectar doping genético são, contudo, desconhecidos. 
O objetivo da presente revisão de literatura foi discutir biossíntese, variantes genéticas, manipulação 
genética e farmacológica, e doping relacionado à via da MSTN. Como será concluído do manuscrito, 
a MSTN emerge como uma molécula promissora para combater doenças atróficas musculares e para 
gerar muitas discussões devido à sua possível utilização em doping genético.
Unitermos: Miostatina. Miostatina/variantes genéticas. Miostatina/inibidores farmacológicos. Doping 
genético. Desempenho atlético. Músculo esquelético.
INTRODUCTION
Myostatin (MSTN), or growth and differentiation 
factor 8 (GDF-8), is a member of the transforming growth 
factor (TGF-β) family which acts at physiological levels 
to limit muscle mass (Lee, 2010; Lee, Glass, 2011; Wang, 
McPherron, 2012). Genomic and molecular studies in 
multiple species have demonstrated that mutations in the 
MSTN gene promote dramatic increase in muscle mass as 
a result of the combination of hypertrophy and hyperplasia 
(McPherron, Lee, 1997; Zimmers et al., 2002; Schuelke 
et al., 2004; Moscher et al., 2007). MSTN inhibition by 
genetic manipulation and/or drugs also results in hyper-
trophic phenotype, and this can be a promising strategy 
to counteract muscle wasting in a diversity of settings 
(Gilson et al., 2009; Murphy et al., 2010; Heineke et al., 
2010; Bish et al., 2011).
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MSTN is widely studied in animal models (Mosher 
et al., 2007; Kota et al., 2009; Bish et al., 2011; Welle 
et al., 2011; Busquets et al., 2012) but less so in humans 
for ethical reasons (Wagner et al., 2008). For example, 
in 1999, an 18-year-old volunteer in a phase trial died 
after undergoing reactive attachment disorder treatment 
(RAD) to deliver in vivo a gene encoding a deficient liver 
enzyme - ornithine transcarbamilase (Raper et al., 2003). 
Another study reported that the insertion of retrovirus 
resulted in one death among three children with X-linked 
severe combined immunodeficiency (Cavazzana-Calvo 
et al., 2005). It is therefore a complex challenge to 
translate animal therapies to human clinical trials, for 
reasons including: differences in the size of the muscles, 
the nature of the vector, differences in immune responses 
between species and differences in metabolism (Baotina 
et al., 2007).
In addition, MSTN manipulation has major implica-
tions for the treatment of muscle wasting diseases. Gene 
therapy techniques can, however, enable the manipulation 
of biotechnology for illicit use in sport (Mansour, Azzazy, 
2009; McKanna, Toriello, 2010; Oliveira et al., 2011). 
Such a scenario is theoretically possible, but it is not 
known whether any athletes have already resorted to it. A 
much debated issue is whether gene doping can enhance 
human performance among athletes. As mentioned, the 
available data are limited to animal models. 
It is also important to be concerned about adverse 
effects: would MSTN inhibition or knock-out have delete-
rious effects on tissues such as bone and tendons because 
of the disproportional amount of muscle mass? It is known 
that contracting muscle transfers tension to skeletal ele-
ments through connective tissues, and it has already been 
demonstrated (Elashry et al., 2012) that MSTN null mice 
(mice with supra-muscular phenotype) present decreased 
connective tissue content, which can predispose them 
to injury. Another issue in the scientific community and 
sports organizations is the concern to control this type of 
high-tech doping in competitions. As yet there are no anti-
doping methods available to screen and identify transgenic 
athletes, but some studies are underway to develop these 
(Bogani et al., 2011; Scarano et al., 2011; Carter, Flueck, 
2012).
Thus, the aim of the present review is to explore 
the state of the art of MSTN cellular mechanisms, ge-
netic variants and gene/pharmacological manipulation 
for therapeutic purposes and the implications of gene 
doping for athletes. Highwire and PubMed databases 
were consulted for this review using the following terms: 
gene doping, athletes, genes, gene therapy, myostatin and 
skeletal muscle. 
MYOSTATIN BIOSYNTHESIS AND PATHWAY
In 1997, a group led by Se-Jin Lee at Johns Hopkins 
School of Medicine described MSTN for the first time as 
a negative regulator of muscle mass (McPherron et al., 
1997) during screening for novel members of the Trans-
forming Growth Factor Beta (TGF-β) in mammals. With 
the purpose of determining MSTN function, the authors 
disrupted the gene in null mutation mice, which then 
presented significant increase in muscle mass (hypertro-
phy and hyperplasia) when compared to a control group. 
MSTN mutations in cattle (Belgian Blue and Piedmontese) 
associated with the deletion of this protein also result in 
incredible hypertrophy (Buske et al., 2011).
MSTN circulates in the bloodstream and its gene 
encodes a small N-terminal sequence, which is followed 
by a pro-peptide region (latent region) that controls bio-
chemical MSTN action, and a small C-terminal region 
(mature region) that makes the link to Activin Receptor II 
(ACTRIIB) (Lee, 2010). ACTRIIB has a transmembranic 
characteristic, belongs to the serine/treonine kinase family 
and phosphorylates activin receptor I (ACTRI), initiating 
a cascade of intracellular signals by regulatory proteins 
SMAD2 and SMAD3, which, when activated, are trans-
located to the nucleus, thus regulating gene transcription 
(Han, Mitch, 2011). When SMAD2 and 3 are phosphory-
lated, they promote MSTN action through muscle hyper-
trophy inhibition. MSTN blocks the growth of myoblasts 
and inhibits the expression of myogenic regulatory fac-
tors (MRFs), such as myoblast determination protein 1 
(MYOD) (McFarlane et al., 2011). Moreover, classic 
studies show that MSTN negatively regulates the activa-
tion of satellite cells and self-renewal (McCroskery et al., 
2004). In contrast, a recent study reported that inhibiting 
MSTN produces significant hypertrophy, but without early 
activation of satellite cells (Wang, McPherron, 2012).
NATURAL GENETIC VARIANTS
The first case of a human mutation in the MSTN 
gene was described in 2004 (Schuelke et al., 2004), when 
a German newborn presented extraordinary musculature 
(mainly in the arms and legs) compared to a child of the 
same age. By 4.5 years of age, the child was able to hold 
two/three kg dumbbells with his arms extended, and mus-
cle hypertrophy was analyzed by ultrasound at six years 
of age, when the cross sectional area was also 2.5 times 
greater than that of a normal child. It is worth mentioning 
that the child’s mother had previously been an athlete with 
considerable strength (Schuelke et al., 2004). A set of tests 
demonstrated that the child was clinically normal, and a 
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molecular readout of the MSTN gene showed a mutation 
in the intron located between the exons 1 and 2, resulting 
in a premature termination codon (Schuelke et al., 2004). 
This finding was important in future studies to understand-
ing the function of MSTN in the human organism and to 
developing potential therapies or studying the athletic 
phenotypes.
Another study reported a mutation in whippets that 
results in an athletic advantage associated with increased 
muscle mass in this group (Mosher et al., 2007). In this 
study, three groups of racing whippets were assessed: dogs 
who have two copies of the wild type allele (+/+), hetero-
zygous with one wild type allele and one mutant allele (+/
mh) and homozygous for the mutant allele (mh/mh). The 
authors found that 8 out of 12 heterozygous dogs and one 
homozygous mutant had the highest racing grade among 
85 whippets analyzed. Meanwhile, 12 out of 72 wild-type 
individuals performed to this level. The heterozygous dogs 
were the fastest, thereby demonstrating the existence of 
an athletic phenotype for sprint performance, whereas the 
homozygous dogs presented the most robust muscle mass 
phenotype, similarly to other double muscling species.
In 2010, a genetic variant was identified for the first 
time in racehorses, which seems potentially to influence 
athletic performance (muscle power) (Hill et al., 2010) 
and there is evidence showing that thoroughbred horses 
have more muscle mass and present phenotypes related to 
increased strength in comparison to other horse species. 
The authors investigated the sequence variation of the 
MSTN gene, which contains three exons and spans 6,172 
bp in chromosome 18 (Hill et al., 2010). Future functional 
genomics studies may reveal whether the mutation has a 
significant impact on MSTN gene expression and this find-
ing may be a first step towards selecting athletes based on 
genetics and also to boosting performance through genetic 
manipulation.
GENE THERAPY AND MYOSTATIN INHIBI-
TING DRUGS
Progress in molecular biology has enabled research-
ers to manipulate genes for therapeutic purposes. Human 
gene therapy is the transference of genetic material to hu-
man cells in order to treat or prevent diseases (Tilemann 
et al., 2012). Gene therapy uses genetic material, such as 
RNA and DNA, or even genetically modified cells (Kole 
et al., 2012; Gambari, 2012). It consists in artificial gene 
transfection to the organism, whereby the inserted gene 
ultimately leads to the increase and/or reduction in ex-
pression of one or more genes (Gaffney, Parisotto, 2007). 
The genetic material can be transferred by both direct (in 
vivo) and indirect (ex vivo) methods (Zhang et al., 2012; 
Gregory-Evans et al., 2012). The in vivo method consists 
in inserting the gene directly into the organism by subcu-
taneous, intramuscular, intravenous or intravascular injec-
tion (Zhang et al., 2012), while the ex vivo method consists 
of withdrawing cells from the patient, modifying them in 
the laboratory and reintroducing them into the patient. It 
seems that gene therapy will emerge as a promising way to 
treat some diseases, but some limitations associated with 
its adverse effects have to be addressed (Gregory-Evans 
et al., 2012).
In vivo injections of MSTN blockade antibody 
(JA16 neutralizing monoclonal antibody) in MDX mice 
increase both skeletal muscle hypertrophy and strength, 
and can be used as a therapeutic strategy (Bogdanovich 
et al., 2002). Another neutralizing MSTN antibody called 
MYO-029 was developed by Wyeth Pharmaceuticals to 
treat muscular dystrophies. In 2008, a clinical trial with 
MYO-029 was conducted on patients with different 
types of muscular dystrophies (Wagner et al., 2008). This 
“giant collaborative” project comprised a double-blind, 
placebo-controlled and randomized study with analysis 
of clinical, functional and serum parameters. Despite 
having no effect on muscle hypertrophy and function, 
treatment with MYO-029 proved to be quite safe in those 
patients. In another study, the contractile properties of 
single muscle fibers were evaluated using MYO-029 and 
muscle improvement occurred in four of the five patients 
treated, despite the fact that no quantitative improvement 
in muscle strength was observed (Krivickas et al., 2009).
An alternative strategy to the antibodies is a soluble 
version of the activin type II receptor (ACTRIIB/Fc), 
which induces dramatic muscle growth (Lee et al., 2010). 
Previous findings have shown, for example, that the injec-
tion of two other proteins (a control mouse monoclonal 
antibody and the myostatin propeptide fused to an Fc do-
main) had no effect compared to the PBS group (control). 
However, ACTRIIB/Fc caused growth of 32-40%, which 
was paralleled by an increase in the cross-sectional area of 
the gastrocnemius and plantaris muscles (Lee et al., 2005). 
In addition, this study found that the effect of the soluble 
receptor is attenuated but not eliminated in MSTN-/- mice, 
suggesting that at least one other ligand (GDF-11) in addi-
tion to MSTN normally functions to limit muscle growth.
Another elegant study reported that ACTRIIB/Fc 
treatment improved the success of human myoblast trans-
plantation more than threefold, as evaluated by the number 
of human dystrophin-positive myofibers (Fakhfakh et al., 
2012). In vitro experiments showed that this approach 
increased the differentiation of human myoblasts through 
an up-regulation of the regulatory genes responsible for 
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myogenesis such as MyoD, resulting in myotube fusion 
and maturation. In order to better demonstrate the under-
lying mechanisms, forced swimming was performed and 
ACTRII2B treatment combined with exercise. Finally, 
it is important to point out that some clinical trials using 
ACTRIIB are already underway (Rahimov et al., 2011).
The protein follistatin was first identified as a single 
chain-polipeptide with weak inhibitory activity toward 
follicle-stimulating hormone secretion by anterior pitu-
itary cells and was later demonstrated to be an activin-
binding protein (Rodino-Kaplac et al., 2009). It is an 
MSTN binding protein that can inhibit MSTN and activin 
both in vitro and in vivo. However, due to its effects on the 
suppression of the hypothalamic-pituitary-gonadal axis, a 
spliced form of Follistatin was developed, which can be 
delivered by adeno associated virus (AAV) into muscles. 
Furthermore, no adverse effect has been detected using 
this approach (Kota et al., 2009). Another study described 
a powerful method using a one-time gene administration 
of MSTN inhibitor protein, which enhanced muscle mass 
and strength in normal and dystrophic mouse models for 
more than two years (Haidet et al., 2008).
Studies with RNA interference have come to the fore 
in recent years, and they consist in utilizing small frag-
ments of RNA that bind to larger RNAs, promoting their 
inhibition (Kohler et al., 2011). Recently, it was reported 
that transgenic -zebra-fish receiving a microinjection of 
double-stranded biological RNA MSTN silencing pre-
sented hypertrophy and hyperplasia. RNAi for MSTN was 
also able to reduce MSTN mRNA and protein, increasing 
muscle mass and fiber size in vivo (Acosta et al., 2005).
A more recent study reported the use of antisense oli-
gonucleotides to manipulate MSTN pre-RNA splicing and 
knock-down MSTN expression - this study provided proof
 of principle of how MSTN knockout can be 
achieved by exon skipping (Kang et al., 2011). In com-
parison to virus mediated approaches, the use of these 
tools has advantages relating, for example, to the safety 
of uncontrolled insertion into the genome. 
GENE DOPING AND PHYSICAL PERFOR-
MANCE
According to World Anti-Doping Agency (WADA), 
gene doping is the non therapeutic manipulation of cells, 
genes, genetic elements or modulation of gene expres-
sion with the aim of increasing athletic ability (Gaffney, 
Parizzoto, 2007).
MSTN inhibition or deletion by gene therapy, 
drugs, genetic manipulation and mutations can result in 
hypertrophy and some studies have demonstrated en-
hancement of physical performance (Mosher et al., 2007; 
Lebrasseur et al., 2009; Santiago et al., 2011; Busquets 
et al., 2012). A question that remains to be answered 
is whether the increase in performance seen in animal 
models could be translated to humans. At the moment, the 
data show that MSTN plays a prominent role in muscle 
mass, but to associate this with improved performance 
is quite speculative.
In order to test the hypothesis that inhibition of 
MSTN preserves muscles from sarcopenia (Lenk et al., 
2011), MSTN inhibition was investigated in old mice. 
Mice received an MSTN antibody (PF-354) and body 
composition, muscle weight and physical capacity were 
evaluated by means of various tests, including the time 
in treadmill until exhaustion test, ambulatory activity, 
grip strength and tetanic force. Glucose tolerance, insulin 
sensitivity, oxygen consumption and levels of protein 
expression and phosphorylation were also investigated to 
identify the mechanisms involved in the MSTN pathway 
under these experimental conditions. The anabolic effect 
of PF-354 was associated with a reduction in SMAD3 
phosphorylation (LeBrasseur et al., 2009). Exercise 
training associated with PF-354 increased physical per-
formance significantly, showing the potential impact of 
both strategies in counteracting sarcopenia. 
Another elegant study published in the journal Sci-
ence Translational Medicine demonstrated the efficiency 
of inhibiting MSTN in primates (Kota et al., 2009). It 
was developed a Follistatin isoform (AVV1-FS344) that 
prevents MSTN from binding to ACTRIIB receptors 
on muscle cells and induces increased muscle mass and 
strength, without affecting the morphology and function 
of major organs. Thus, AAV1-FS344 would be of interest 
to the athletic community, probably because it is safer than 
other methods of inhibiting MSTN.
Meanwhile, Morine et al. (2010) described a method 
in which they used adeno-associated virus vector (AVV) 
to over-express dominant negative MSTN exclusively 
on the liver of mice. This MSTN inhibition resulted in 
increased muscle mass and strength in control mice and 
in Duchenne muscle dystrophy models. The increase in 
muscle mass was pronounced in the soleus, quadriceps, 
tibialis anterior and extensor digitorum longus, although 
no effect on diaphragm and ventricular hypertrophy were 
observed (Morine et al., 2010). Transfection into the liver 
is an interesting strategy for inhibiting MSTN in a range of 
pathologies because transferring to the liver has a series of 
advantages compared to other experimental approaches. 
The use of adeno-associated virus (AVV) transfected to 
the liver requires only one application to cause consider-
able transgene expression, for example. Accordingly, the 
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authors explain that this method would be efficient in large 
animals and is very difficult to detect, which could attract 
interest from athletes. 
Some recent studies have demonstrated that MSTN 
can function not only as a modulator of muscle mass, but 
can also play a role in metabolism or even in endurance 
phenotype. It is well established that skeletal muscle has 
different fiber types which exhibit specific contractile and 
metabolic characteristics. In a well designed study, Can-
dena et al. (2010) investigated the effects of a hypertrophy-
inducing substance called ACE-031 (a soluble receptor 
form of activin IIB). In the soleus muscle, the total number 
(type I and II) of each fiber type was similar between the 
control and treated groups. The new finding was that both 
fast and slow fibers hypertrophied, providing evidence 
that blocking the MSTN pathway can improve strength, 
hypertrophy and resistance to fatigue concomitantly. 
This study was the first to demonstrate the versatility of 
this molecule not only in enhancing strength, but also in 
improving endurance capacity.
Another study reinforces the view that other pheno-
types in addition to increased muscle mass might occur 
in skeletal muscle. MSTN null mice (MSTN-/-) display 
increased myofibre hypertrophy and hyperplasia, but 
compromised muscle force. In this study, the mice were 
subjected to swimming and treadmill exercise in order to 
evaluate morphological and molecular parameters (Mat-
sakas et al., 2012). Exercise restored muscle function, 
increased muscle capillary density and the expression of 
key genes involved in oxidative metabolism. This find-
ing is important because MSTN inhibition may induce 
growth of skeletal muscles without improving function, 
but exercise training may reprogram muscle to increase 
its strength, and this could be an attractive prospect for 
athletes. 
Beyond skeletal muscle mass regulation, MSTN 
plays a potential role in the modulation of adipose tis-
sue phenotype and metabolism. An interesting study 
demonstrated that pharmacological inhibition of AC-
TRIIB induced an increase in brown adipose tissue (BAT) 
through a fine-tuning mechanism that involves activation 
of myoglobin expression and PGC-1α in BAT. In addi-
tion, MSTN inhibition enhances mitochondrial function 
and uncoupled respiration, thereby increasing energy 
expenditure (Fournier et al., 2012). Another study found 
that suppressed ACTRIIB can treat diet-induced obesity 
and induce a brown fat-like thermogenic gene program in 
white adipose tissue (Koncarevic et al., 2012). The results 
of these studies can have major implications for sports 
that require a low percentage of adipose tissue and for the 
treatment of obesity.
CONCLUSION
MSTN was discovered 15 years ago and, since 
then, important advances have been made in an attempt 
to develop outstanding therapeutic strategies (pharmaco-
logical or/and genetic manipulation). Increase in muscle 
mass is the most evident phenotype triggered by MSTN 
inhibition. Most of the elegant studies were carried out in 
animals and it is questionable both whether the findings 
observed in animals could be translated to humans, and 
whether MSTN inhibition results in improved physical 
performance, as demonstrated in Figure 1.
Beyond improving power/strength phenotypes 
in models of muscle dystrophies and other conditions, 
MSTN inhibition can potentially induce thermogenesis 
and fat loss. However, connective tissue is affected by this 
approach, and it is a major challenge to increase muscle 
mass while preserving connective tissue. At the same time, 
the development of these concepts raises the possibility of 
genetic manipulation in the world of sport. In this scenario, 
a good many athletes would no doubt subject themselves 
to this kind of illegal procedure, even bearing in mind that 
transfection may produce a number of adverse effects. 
Consequently, the organizations that regulate amateur 
and professional sports need to be prepared to discuss 
these issues.
FIGURE 1 - Potential effects of MSTN inhibition.
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